Impaired burn wound healing in the elderly represents a major clinical problem. Hypoxia-inducible factor-1 (HIF-1) is a transcriptional activator that orchestrates the cellular response to hypoxia.

Ong et al. 16 performed a meta-analysis of data from six randomized, controlled trials, published from 1966 through 2004, that compared early excision of burns with wound dressing and grafting ...

The wounds were self-treated at home with several "burn ointments" for four days. On admission the burned area was covered with a greenish-yellow adherent eschar.

And an eschar is a sign that a wound is too dry to heal as fast as possible. Having noted that, a crust is the best nature can do in many situations. It is protective.

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns. Triggers $7.5 million milestone payment from Vericel ...

Results from DETECT, the phase 3 study that supported the FDA approval of NexoBrid for the treatment of severe thermal burns, was recently published in the Journal of Burn Care & Research, Vericel ...

MediWound Ltd (NASDAQ: MDWD) has announced topline results from Phase 3 pediatric study with NexoBrid to treat severe thermal burns. The 145-subject study met its three primary endpoints. NexoBrid ...

The product selectively removes burn eschar within 4 hours without harming surrounding ... The estimated median time to 95% or greater wound closure was 31 days for the NexoBrid arm and 36 days ...

Met Primary and All Secondary Endpoints with Statistically Significant Results Compared with Control GroupConference call with MediWound management and U.S. key opinion leader begins today ...

The product selectively removes burn eschar within 4 hours without harming surrounding viable tissue. The approval was based on data from 2 clinical trials (ClinicalTrials.gov Identifier ...